Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015 – Genetic Engineering & Biotechnology News
CNBC |
Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015
Genetic Engineering & Biotechnology News Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T-cell cancer immunotherapy indicated for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II … Juno Therapeutics beats earnings expectations, announces it will drop problem cancer drugGeekWire Juno Therapeutics’ Q4 Financial Results Overshadowed by Pipeline SetbackMadison.com Juno ends flagship drug trial after deaths and FDA suspensionsPuget Sound Business Journal (Seattle) KFGO –OncLive all 30 news articles » |
Genetic Literacy Project |
‘Superbugs’ could be killed with ‘genetic chainsaw’ version of gene editor CRISPR
Genetic Literacy Project When folks talk about the gene-editing tool CRISPR, they’re usually talking about CRISPR-Cas9, a combination of DNA and enzymes that together act like scissors to cut and paste genes. CRISPR-Cas9 has already been hailed a potential game changer in … |
